Urea has a critical role in urinary concentration. Mice lacking the inner medullary collecting duct (IMCD) urea transporter A1 (UT-A1) and urea transporter A3 (UT-A3) have very low levels of urea permeability and are unable to concentrate urine. To investigate the role of UT-A1 in the concentration of urine, we transgenically expressed UT-A1 in knockout mice lacking UT-A1 and UT-A3 using a construct with a UT-A1 gene that cannot be spliced to produce UT-A3. This construct was inserted behind the original UT-A promoter to yield a mouse expressing only UT-A1 (UT-A1 +/+ /UT-A3 2/2 ). Western blot analysis demonstrated UT-A1 in the inner medulla of UT-A1
Immunohistochemistry in UT-A1
+/+ /UT-A3 2/2 mice also showed negative UT-A3 staining in kidney and other tissues and positive UT-A1 staining only in the IMCD. Urea permeability in isolated perfused IMCDs showed basal permeability in the UT-A1 +/+ /UT-A3 2/2 mice was similar to levels in wild-type mice, but vasopressin stimulation of urea permeability in wild-type mice was significantly greater (100% increase) than in UT-A1 +/+ /UT-A3 2/2 mice (8% increase). Notably, basal urine osmolalities in both wild-type and
UT-A1
+/+ /UT-A3 2/2 mice increased upon overnight water restriction. We conclude that transgenic expression of UT-A1 restores basal urea permeability to the level in wild-type mice but does not restore vasopressin-stimulated levels of urea permeability. This information suggests that transgenic expression of UT-A1 alone in mice lacking UT-A1 and UT-A3 is sufficient to restore urine-concentrating ability. Urea plays a critical role in the urinary concentrating mechanism and in the regulation of water balance. 1, 2 Maximal urine-concentrating ability is decreased by protein deprivation and restored by urea infusion (reviewed in Klein et al. 3 ). Urea transporter A1/urea transporter A3 (UT-A1/UT-A3), [4] [5] [6] [7] urea transporter A2 (UT-A2), 8 urea transporter B1 (UT-B1), [9] [10] [11] and UT-A2/UT-B1 12 knockout mice each have urineconcentrating defects. The UT-A1/UT-A3 knockout mouse has a severe urine-concentrating defect. Thus, any hypothesis regarding the mechanism by which the kidney concentrates urine needs to include some effect derived from urea and urea transporters, especially UT-A1 and/or UT-A3. The mechanism by which urine concentration occurs in the inner medulla remains controversial.
The most widely accepted mechanism remains the passive reabsorption of NaCl, in excess of solute secretion, from thin ascending limbs of the loops of Henle. 13, 14 However, the passive mechanism hypothesis is not universally accepted. Studies of the UT-A1/ UT-A3 knockout mouse have been interpreted both to refute and support the passive mechanism. [15] [16] [17] Regardless, knockout of UT-A1 and UT-A3 results in a severe urine-concentrating defect. 4, 5 UT-A1 is expressed in the inner medullary collecting duct (IMCD) apical plasma membrane. 18 UT-A3 is expressed in the IMCD basolateral plasma membrane, but is also detected in the apical plasma membrane following stimulation by vasopressin. 19 Vasopressin increases both the phosphorylation and the apical plasma membrane accumulation of UT-A1 and UT-A3 in freshly isolated suspensions of rat IMCDs, 19, 20 and increases facilitated urea transport in perfused terminal IMCDs. 21 Because both UT-A1 and UT-A3 are present, it is not possible to determine the relative contribution of each isoform to urea transport.
Both UT-A1 and UT-A3 are under the control of UT-A promoter I; there is a second, internal promoter, UT-A promoter II, which controls UT-A2. [22] [23] [24] UT-A3 is essentially the N-terminal half of UT-A1, with the sole difference being that UT-A3 has a unique amino acid at its C-terminus and a unique 39-untranslated region. 25 UT-A2 is essentially the C-terminal half of UT-A1, with a unique exon that encodes the N-terminus of UT-A2. [22] [23] [24] 26 Thus, the UT-A gene structure precludes making a UT-A3 knockout mouse without also knocking out UT-A1. The goal of this study was to use an innovative approach to make a mouse expressing UT-A1 but lacking UT-A3 by genetically engineering UT-A1 back into a UT-A1/UT-A3 knockout mouse. The transgenic expression of UT-A1 in knockout mice lacking UT-A1 and UT-A3 allows us to examine the role of UT-A1 in producing a concentrated urine without the influence of UT-A3.
RESULTS

Generation of UT-A1
+/+ /UT-A3 2/2 Mice Our colony of UT-A1/UT-A3 knockout mice were rederived from breeding stock kindly provided by Dr. Knepper (National Institutes of Health [NIH]). 4, 7 A UT-A1 DNA construct was prepared with the full-length exon sequence for UT-A1 behind the native UT-A1 promoter, and was designed to eliminate possible cleavage sites so that the shorter UT-A3 version of this protein is not made (Figure 1 ). The final UT-A1 construct has the following structure: the 59-end consists of a 4.3-kb stretch of the mouse UT-A1 promoter I and is continued beyond the transcription initiation site until the end of the first exon. This 4.3-kb promoter length has been shown to guide expression of a reporter gene to principal cells in the terminal IMCD. 27 Following the first exon, an intron was included to increase the expression of the transgene 28 ; we used intron 1 of the rabbit b-globin gene instead of intron 1 of UT-A1, which would be much too long (25 kb). This was followed by the cDNA of UT-A1 starting at the sequence corresponding to exon 2 until the end of the 39-untranslated region, including the polyadenylation sites.
This construct was introduced into wild-type (WT) C57Bl6 mice. Over 15 generations, the mice were back-bred to UT-A1/ UT-A3 knockout mice, selecting for the transgene and absence of the native UT-A gene to achieve a line of mice that are homozygous for the UT-A1 gene without the UT-A3 gene and produce the proteins as shown in Figure 2 . WT C57Bl6 mice show the 97-and 117-kDa UT-A1 protein (panel A, left lanes) as well as the UT-A3 glycoproteins (panel B, left lanes). These are absent in the UT-A1/UT-A3 knockout mice (panels A and B, right lanes). The UT-A1 +/+ /UT-A3 2/2 mice show UT-A1 protein (panel A, center) with no evidence of UT-A3 (panel B, center). Aquaporin-2 (AQP2) protein was present at comparable levels in WT, UT-A1 +/+ /UT-A3 2/2 , and UT-A1/UT-A3 knockout mice ( Figure 2C ). Immunohistochemistry confirmed the absence of UT-A3 in UT-A1 +/+ /UT-A3 2/2 mice ( Figure 2D ). The positive control for the presence of UT-A3 in the WTmice is provided in the inset micrograph ( Figure 2D , inset). Conversely, while UT-A1 is present in the UT-A1 +/+ /UT-A3 2/2 mice ( Figure 2E ), it is absent in the UT-A1/UT-A3 knockout mice ( Figure 2E inset) . Staining for UT-A1 or UT-A3 in other kidney sections and extrarenal tissues were negative (data not shown), confirming that the targeting construct led to UT-A1 expression only in the IMCD.
Comparison of AQP2 and UT-A1 in hydrated and dehydrated mice was performed by Western blot analysis (Figure 3 ). The abundance of AQP2 was not altered by 24 hours of dehydration in either WT or UT-A1 +/+ /UT-A3 2/2 mice ( Figure  3A) . UT-A1 also showed no statistically significant difference upon dehydration in UT-A1 +/+ /UT-A3 2/2 mice, but was decreased by dehydration in WT mice ( Figure 3B ). The decrease in UT-A1 in the WT mice is similar to the response in rats. 29 Under basal conditions, there was no significant difference between total UT-A1 abundance in WT (1457673) and UT-A1 +/+ /UT-A3 2/2 mice (1156689). However, there was a significant decrease in the abundance of the 117-kDa glycoprotein band and a nonsignificant increase in the abundance of the 97-kDa glycoprotein band in the UT-A1 +/+ /UT-A3 2/2 mice compared with WT mice ( Figure 3C ). Immunofluorescence staining of kidneys from WT and UT-A1 +/+ /UT-A3 2/2 mice with antibodies against AQP2 and p486-UT-A1 was used to show the uniformity of UT-A1 distribution in the inner medulla. The data are presented in pairs of micrographs showing AQP2 staining on the left and p486-UT-A1 staining on the right ( Figure 3D ). From top to bottom, the pairs show WT mice under basal conditions, kidneys from WTmice that were dehydrated for 24 hours, UT-A1 +/+ /UT-A3 2/2 mice under basal conditions, and kidneys from dehydrated UT-A1
2/2 mice. Comparison of AQP2, used as a marker for IMCDs, with p486-UT-A1 shows that all IMCDs in the UT-A1
2/2 mice express UT-A1 in a distribution that is indistinguishable from WT mice. The staining also confirms that the orientation of p486-UT-A1 is at the apical plasma membrane of the IMCDs.
Urea Permeability in the IMCD
The urea permeability of IMCDs from WT, UT-A1
, and UT-A1/UT-A3 knockout mice was measured in microdissected, isolated, perfused tubules. Figure 4A provides individual tubule responses and Figure 4B shows the average urea permeabilities with SEMs. In the WTmice (Figure 4 , triangles), where both UT-A1 and UT-A3 are present, vasopressin (10 210 M) increased basal urea permeability by 100% (n=3, P,0.01).
UT-A1/UT-A3 knockout mice had a very low basal urea permeability with no significant effect of vasopressin (n=3, Figure 4 , circles). These values are consistent with those measured in the original line of UT-A1/UT-A3 knockout mice. 4 The UT-A1 +/+ /UT-A3 2/2 mice had a significantly higher basal urea permeability (36.862.5310 25 cm/s, n=6, Figure 4 , squares) than the UT-A1/UT-A3 knockout mice (6.061.9310 25 cm/s), and a similar basal urea permeability as WTmice (37.162.6310 25 cm/s). The urea permeability of the UT-A1
2/2 mice was slightly increased by vasopressin to 39.762.3310 25 cm/s, although to a significantly lesser extent (8%) than the increase measured in WT mice with both UT-A1 and UT-A3 present (74.362.1310 25 cm/s; 100% increase). Thus, the transgenic expression of UT-A1 in knockout mice lacking UT-A1 and UT-A3 restored basal urea permeability, but vasopressin was unable to stimulate urea permeability.
Urine-Concentrating Ability WT, UT-A1
, and UT-A1/UT-A3 knockout mice were placed in metabolic cages and their urine was collected for 24 hours. Water was withheld for an additional 24 hours while urine was again collected. These determinations were performed many times over a period of 3 years, and urine osmolalities were stable in all three lines of mice over time. The bar graph in Figure 5 provides averaged values for osmolality with and without dehydration collected over this time period. In WT mice, urine osmolality was increased 47% by dehydration (n=12, P,0.01). UT-A1/UT-A3 knockout mice were unable to concentrate their urine above the basal (hydrated) level (n=19, p=NS), consistent with the findings in the original line of UT-A1/UT-A3 knockout mice. 4 The UT-A1
+/+ /UT-A3 2/2 mice showed a 56% increase in urine osmolality in response to dehydration (n=19 hydrated, 45 dehydrated, P,0.001).
Urea excretion for a single experiment comparing eight animals per genotype per treatment is provided in Table 1 . Dehydration for 24 hours caused urine volumes to decrease in all groups. The mmol of urea excreted per day per 100 g body wt was not statistically different between WT and UT-A1 +/+ /UT-A3 2/2 mice. UT-A1/A3 KO mice showed higher levels of urea excretion compared with WT or UT-A1
mice under basal conditions (P,0.01).
Effect of Chronic Vasopressin Administration
We previously showed that 7 days of vasopressin increased AQP2 water channel protein abundance to a similar degree in WT and UT-A1/UT-A3 knockout mice. 7 To determine if the transgenic expression of UT-A1 in mice lacking UT-A1 and UT-A3 would alter the characteristic vasopressinstimulated increase in AQP2 protein abundance, WT, UT-A1 +/+ /UT-A3 2 /2 , and UT-A1/UT-A3 knockout mice were injected twice daily with desmopressin (dDAVP) for 3 days. AQP2 protein abundance was significantly increased to 174622% in the inner medulla of UT-A1
mice (P,0.01, n=8). The increase in AQP2 protein abundance following dDAVP was similar in WT, UT-A1 +/+ /UT-A3 2/2 , and UT-A1/UT-A3 knockout mice ( Figure 6 ).
DISCUSSION
Urea transport across the IMCD is mediated by the two urea transporters expressed in this portion of the collecting duct, UT-A1 (6SEM), n=8 WT and 9 UT-A1 +/+ /UT-A3 2/2 mice. *P,0.05 for the 117-kDa band. The differences in density were not statistically significant (NS) for the 97-kDa band or for total UT-A1 abundance (not shown in figure) . (D) Immunofluorescence staining of AQP2 (left micrographs, red) and p486-UT-A1 (right micrographs, green) in kidney slices from WT and UT-A1 +/+ /UT-A3 2/2 mice under normal hydrated and 24-hour dehydrated conditions. Slides were double-stained and images were collected using wavelength-specific filters. Nuclei were costained with 4',6-diamidino-2-phenylindole. Imaged with a 403 objective as described in Concise Methods.
and UT-A3. Genetic knockout of both UT-A1 and UT-A3 results in a mouse with a very low urea permeability in the IMCD and a profound urine-concentrating defect. [4] [5] [6] [7] Because both UT-A1 and UT-A3 are knocked out, it is not possible to determine the contribution of each urea transporter to the reduction in urea permeability or urine-concentrating ability. One approach would be to genetically engineer mice in which only one of these urea transporters was knocked out. However, the structure of the UT-A gene precludes the selective knockout of only UT-A1 or UT-A3 using conventional approaches. In this study, we used a novel approach of engineering UT-A1 into a UT-A1/UT-A3 knockout mouse to generate a mouse expressing only UT-A1. We used a promoter, UT-A promoter 1, which has been shown to target specifically the IMCD. 27 Using this approach, we were able to create a mouse that has transgenic expression of UT-A1 in knockout mice lacking UT-A1 and UT-A3 only in the IMCD, where it is normally expressed, but lacks UT-A3. The UT-A1 +/+ /UT-A3 2/2 mouse has a basal urea permeability that is similar to WTmice. This suggests that transgenic expression of UT-A1 alone in mice lacking UT-A1 and UT-A3 is sufficient to restore the basal level of urea transport across the IMCD. We did not detect any difference in the qualitative localization of p486-UT-A1 between WT and UT-A1 +/+ /UT-A3 2/2 mice, nor was there any obvious heterogeneity of p486-UT-A1 expression between different IMCDs. Although there was a trend toward decreased UT-A1 abundance in the UT-A1 +/+ /UT-A3 2/2 mice, the average band density for UT-A1 in WT mice was not statistically different from the UT-A1 abundance in the UT-A1 +/+ /UT-A3 2/2 mice. However, there was a decrease in the abundance of the 117-kDa glycoform of UT-A1 (discussed below). Thus, the transgenic expression of UT-A1 in UT-A1/UT-A3 knockout mice does not recapitulate the native pattern of UT-A1 glycoprotein expression observed in WT mice. There was no difference in basal urea permeability or urine-concentrating ability between WT and UT-A1
2/2 mice. These findings suggest that restoration of a normal level of basal urea transport by transgenic expression of UT-A1 in UT-A1/UT-A3 knockout mice is sufficient to produce concentrated urine.
In contrast, the UT-A1 +/+ /UT-A3 2/2 mouse has a markedly reduced level of vasopressin-stimulated urea permeability compared with WT mice. Vasopressin increased urea permeability by only 8%, as compared with doubling urea permeability in WT mice. The reason for the lack of an increase in urea permeability in response to vasopressin is not due to an inability of the kidney to respond to vasopressin, because AQP2 protein abundance and urine osmolality both increased following chronic vasopressin administration. One possible explanation is that the absence of UT-A3, which is the primary urea transporter in the basolateral membrane, changes the rate-limiting membrane from apical to basolateral. R. Star showed that phloretin-inhibitable urea transport is present in both the apical and basolateral membranes, but that the apical membrane was rate-limiting due to the smaller surface area. 30 The transgenic expression of UT-A1 in the apical membrane, generating a highly permeable apical membrane, without UT-A3 in the basolateral membrane, may change the rate-limiting barrier to the basolateral membrane. If so, then it may not be possible for vasopressin to stimulate urea permeability above the basal level.
While UT-A3 is detected only in the basolateral membrane under basal conditions, it is detected in the apical membrane in vasopressin-treated animals. 19 Thus, another possible explanation for the lack of a vasopressin-mediated increase in urea permeability is that UT-A3 in the apical membrane makes a key contribution to the vasopressin-stimulated increase in urea permeability. X-ray crystallographic studies of urea transporters from the bacterium Desulfovibrio vulgaris suggest that the functional unit is a homotrimer. 31 By analogy, it has been suggested that the functional unit in the IMCD is a heterodimer of UT-A1 and UT-A3. 31 We previously showed that UT-A1 and UT-A3 do not coimmunoprecipitate. 19 The present findings also go against this hypothesis because basal urea permeability is similar in WT and UT-A1 +/+ /UT-A3 2/2 mice. We cannot rule out that UT-A1 and UT-A3 form a heterodimer only in the presence of vasopressin. If a heterodimer formed only in response to vasopressin, this would imply that UT-A1 alone is the functional unit under basal conditions, and that the functional structural unit for urea transport is different under basal compared with post vasopressin-stimulated conditions.
We previously suggested an association between the abundance of the 117-kDa glycoform of UT-A1 and the ability of vasopressin to stimulate urea transport. 32 Thus, a third possible explanation for the lack of vasopressin stimulation of urea transport is the decrease in the abundance of the 117-kDa glycoform of UT-A1 in UT-A1 +/+ /UT-A3
mice. Current studies have been unable to determine the reason for the decrease in the 117-kDa glycoform, or whether it is related to the absence of UT-A3 or to the observation that transgenic expression of UT-A1 in knockout mice lacking UT-A1 and UT-A3 does not recapitulate the native pattern of UT-A1 glycoprotein expression observed in WT mice. The restoration of nearly normal urine-concentrating ability in the UT-A1 +/+ /UT-A3 2/2 mouse, despite the lack of vasopressin-stimulation of urea transport, was surprising. One possible interpretation is that transgenic expression of UT-A1 alone results in sufficient urea reabsorption to facilitate nearly normal urine-concentrating ability. In other words, restoring basal urea permeability may be sufficient to restore nearly normal urine-concentrating ability following 24 hours of dehydration. It is possible that a more profound stress, such as a longer period of dehydration, may elicit a difference between WT and UT-A1 +/+ /UT-A3 2/2 mice. However, such prolonged studies were not permitted by our Institutional Animal Care and Use Committee.
In summary, we used a novel approach to engineer a mouse with transgenic expression of UT-A1 alone in knockout mice lacking UT-A1 and UT-A3 in the IMCD. Transgenic expression of UT-A1 restores basal urea permeability to the level measured in WT mice but does not restore vasopressin-stimulated levels of urea permeability. This suggests that transgenic expression of UT-A1 alone in mice lacking UT-A1 and UT-A3 is sufficient to restore urea-concentrating ability.
CONCISE METHODS
Animals
All animal protocols and procedures were approved by the Emory University Animal Care and Use Committee. Mice were environmentally acclimated in metabolic cages for 24 hours, then urine was collected for another 24 hours. Finally, water was withheld for an additional 24 hours and urine was collected to determine urineconcentrating ability. Urine osmolality was determined using a Wescor vapor pressure osmometer.
Sample Preparation
In some cases, mice were treated with dDAVP, a V 2 -selective vasopressin agonist. WT, UT-A1
, and UT-A1 (UT-A1/A3 knockout) mice were injected subcutaneously, twice daily, for 3 days with dDAVP 8 mg/kg per day. Following euthanasia, organs were removed and homogenized in ice-cold isolation buffer containing triethanolamine 10 mM, sucrose 250 mM, pH 7.6, leupeptin 1 mg/ml, and PMSF 2 mg/ml, sheared through a 26G insulin syringe, and SDS added to a final concentration of 1% SDS for Western blot analysis of total cell lysate. The kidneys were removed and dissected into cortex, outer medulla, and inner medulla, then the tissue was prepared as described above. Total protein in each sample was measured by a modified Lowry method (Bio-Rad DC protein assay reagent, BioRad, Richmond, CA).
Western blotting was performed as previously described. 33 Proteins (20 mg/lane) were size-separated by SDS-PAGE, then electroblotted to polyvinylidene difluoride membranes as described previously. 33 Blots were blocked with 5% nonfat dry milk in Tris-buffered saline ([TBS] 20 mM Tris HCl, 0.5 M NaCl, pH 7.5) at room temperature for 1 hour, then incubated with our polyclonal antibody to the C-terminus of UT-A1 overnight at 4°C. 33 Blots were washed three times in TBS with 0.5% Tween-20 (TBS/Tween) and then incubated with Alexa Fluor 680-linked anti-rabbit IgG (Molecular Probes, Eugene, OR). Blots were washed two times with TBS/Tween, and then the bound secondary antibody was visualized using infrared detection with the Licor Odyssey protein analysis system.
Tubule Perfusion
Terminal IMCDs from WT, UT-A1 +/+ /UT-A3 2/2 , and UT-A1/ UT-A3 knockout mice were collected, mounted, and perfused as described previously. 21, 34 To measure basal urea permeability, three collections were made 45 minutes after warming the tubules to 37°C. Next, vasopressin (10 210 M) or vehicle was added to the bath solution. After a 20-minute equilibration period, three collections were made. The collected solutions were assayed for urea content by ultramicrofluorometry. Urea flux was calculated as described previously. 21 
Immunohistochemistry
Mice were injected subcutaneously with vasopressin 45 minutes prior to perfusion and paraformaldehyde fixation, and paraffin embedding as described previously. 7 Paraffin sections of 4-mm thickness were sliced. Sections were dewaxed and hydrated in preparation for immunostaining as previously described. 35 Sections were incubated overnight at 4°C with the following primary antibodies: AQP2, c-terminal UT-A1, and MQ2 anti-UT-A3. Slides were washed free of primary antibody and then incubated for 2 hours in peroxidase-conjugated secondary antibody (donkey anti-rabbit IgG). Diaminobenzidine and 35% H 2 O 2 were added to detect peroxidase activity identifying the primary antibodies. Slides were also stained with Mayers hematoxylin to visualize nuclei. Stained sections were visualized using a bright field on an Olympus IX71 inverted microscope. For immunofluorescence staining, the primary antibodies were goat anti-AQP2 (Santa Cruz Biotechnology) and rabbit anti-phospho-486-UT-A1 (prepared for our laboratory by Phosphosolutions). The fluorescent secondary antibodies were Alexa 546 donkey anti-goat IgG (Life Technologies) for AQP2 identification and Alexa 488 goat anti-rabbit IgG to identify anti-UT-A1. Visualization of immunofluorescence staining was accomplished with appropriate filter selections on the Olympus IX71 microscope. IMCDs were imaged with a 403 objective. Slices were double-stained for both AQP2 and UT-A1. All slides were costained with 49,6-diamidino-2-phenylindole to identify nuclei.
Statistical Analyses
All data are presented as mean6SEM. A t test was used to test two groups. ANOVA was used to test more than two groups, followed by Fisher least significant difference (protected t test) 36 to determine which groups were significantly different. The criterion for statistical significance was set as P,0.05.
